The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Trastuzumab emtansine: mechanisms of action and drug resistance
Open accessAbstract
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment of advanced breast cancer. T-DM1 is currently being evaluated as adjuvant treatment for early breast cancer. It has several mechanisms of action consisting of the anti-tumor effects of trastuzumab and those of DM1, a cytotoxic anti-microtubule agent released within the target cells upon degradation of the human epidermal growth factor receptor-2 (HER2)-T-DM1 complex in lysosomes. The cytotoxic effect of T-DM1 likely varies depending on the intracellular concentration of DM1 accumulated in cancer cells, high intracellular levels resulting in rapid apoptosis, somewhat lower levels in impaired cellular trafficking and mitotic catastrophe, while the lowest levels lead to poor response to T-DM1. Primary resistance of HER2-positive metastatic breast cancer to T-DM1 appears to be relatively infrequent, but most patients treated with T-DM1 develop acquired drug resistance. The mechanisms of resistance are incompletely understood, but mechanisms limiting the binding of trastuzumab to cancer cells may be involved. The cytotoxic effect of T-DM1 may be impaired by inefficient internalization or enhanced recycling of the HER2-T-DM1 complex in cancer cells, or impaired lysosomal degradation of trastuzumab or intracellular trafficking of HER2. The effect of T-DM1 may also be compromised by multidrug resistance proteins that pump DM1 out of cancer cells. In this review we discuss the mechanism of action of T-DM1 and the key clinical results obtained with it, the combinations of T-DM1 with other cytotoxic agents and anti-HER drugs, and the potential resistance mechanisms and the strategies to overcome resistance to T-DM1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 2×
“Defects in the PTEN-PI3K/AKT pathway [26]”
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 946
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Junttila, T. T., Akita, R. W., Parsons, K., Fields, C., Lewis Phillips, G. D., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829
The Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Death through a tragedy: mitotic catastrophe
Vakifahmetoglu, H., Olsson, M., & Zhivotovsky, B. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.47 · Cited by 700
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 523
Self-citationAustin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 496
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Niikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Mechanisms of Taxol-induced cell death are concentration dependent.
Torres, K. E., & Horwitz, S. B. (1998) · PubMed · Cited by 385
Cuello, M. A., Ettenberg, S. A., Clark, A. S., Keane, M., Posner, R. H., Nau, M. M., Dennis, P. A., & Lipkowitz, S. (2001) · PubMed · Cited by 370
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
Mitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 314 · cited 2×
“T-DM1 treatment results in defective intracellular trafficking of the HER2 protein [18], which is not in disagreement with a hypothesis that mitosis is not the only target of anti-microtubule agents, but rather trafficking on the microtubules [34].”
BackgroundRitchie, M., Tchistiakova, L., & Scott, N. (2013) · mAbs · doi:10.4161/mabs.22854 · Cited by 312
Drug Carriers in Biology and Medicine
SHAW, I. H. (1980) · Biochemical Society Transactions · doi:10.1042/bst0080768a · Cited by 288
Motoyama, A. B., Hynes, N. E., & Lane, H. A. (2002) · PubMed · Cited by 286
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells
Morse, D. L., Gray, H., Payne, C. M., & Gillies, R. J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0130 · Cited by 283
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S., Ab, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3546 · Cited by 266
Cell killing by antibody–drug conjugates
Kovtun, Y. V., & Goldmacher, V. S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.010 · Cited by 246
Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers
Mohsin, S. K., Weiss, H. L., Gutierrez, M. C., Chamness, G. C., Schiff, R., DiGiovanna, M. P., Wang, C.-X., Hilsenbeck, S. G., Osborne, C. K., Allred, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.661 · Cited by 244
An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Takara, K., Sakaeda, T., & Okumura, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775201965 · Cited by 236
Arribas, J., Baselga, J., Pedersen, K., & Parra-Palau, J. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3795 · Cited by 236
Barok, M., Isola, J., Pályi-Krekk, Z., Nagy, P., Juhász, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0766 · Cited by 231
Self-citationKomlodi-Pasztor, E., Sackett, D. L., & Fojo, A. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0999 · Cited by 227
Barok, M., Tanner, M., Köninki, K., & Isola, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2868 · Cited by 226
Self-citationHuober, J., Fasching, P. A., Barsoum, M., Petruzelka, L., Wallwiener, D., Thomssen, C., Reimer, T., Paepke, S., Azim, H. A., Ragosch, V., et al. (2012) · The Breast · doi:10.1016/j.breast.2011.07.006 · Cited by 223
Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3704 · Cited by 221
CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin
Cabral, F., Sobel, M. E., & Gottesman, M. M. (1980) · Cell · doi:10.1016/0092-8674(80)90231-7 · Cited by 198
Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D., Schaefer, G., Miller, K., Andre, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198
Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Le Mercier, I., Poujol, D., Sanlaville, A., Sisirak, V., Gobert, M., Durand, I., Dubois, B., Treilleux, I., Marvel, J., Vlach, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3058 · Cited by 195
Drug carriers in biology and medicine
Gregoriadis, G. (1979) · Academic Press eBooks · Cited by 186
HER-2/neu expression in primary and metastatic breast cancer
Lower, E. E., Glass, E., Blau, R., & Harman, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9931-6 · Cited by 171
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Barok, M., Tanner, M., Köninki, K., & Isola, J. J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.002 · Cited by 157
Self-citationHernández‐Vargas, H., Palacios, J., & Moreno‐Bueno, G. (2006) · Oncogene · doi:10.1038/sj.onc.1210102 · Cited by 155
Pályi‐Krekk, Z., Barok, M., Isola, J. J., Tammi, M., ̋si, J. S., & Nagy, P. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.018 · Cited by 149
Self-citationLoi, S., Michiels, S., Lambrechts, D., Fumagalli, D., Claes, B., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Piccart, M. J., Joensuu, H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt121 · Cited by 149
Self-citationYao, E. S., Zhou, W., Lee-Hoeflich, S. T., Truong, T., Haverty, P. M., Eastham‐Anderson, J., Lewin‐Koh, N., Gunter, B., Belvin, M. P., Murray, L. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2814 · Cited by 134
Wardley, A. M., Pivot, X. B., Morales-Vásquez, F., Zetina, L. M., Gauí, M. D. F. D., Reyes, D. O., Jassem, J., Barton, C. M., Button, P., Hersberger, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6531 · Cited by 127
Kono, K., Takahashi, A., Ichihara, F., Sugai, H., Fujii, H., & Matsumoto, Y. (2002) · PubMed · Cited by 126
Perez, E. A., Dueck, A. C., McCullough, A. E., Chen, B., Geiger, X. J., Jenkins, R. B., Lingle, W. L., Davidson, N. E., Martino, S., Kaufman, P. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2642 · Cited by 106
Maytansine binding to the vinblastine sites of tubulin
Bhattacharyya, B., & Wolff, J. (1977) · FEBS Letters · doi:10.1016/0014-5793(77)80075-6 · Cited by 100
Schäller, G., Fuchs, I. B., Gonsch, T., Weber, J., Kleine-Tebbe, A., Klare, P., Hindenburg, H.-J., Lakner, V., Hinke, A., & Bangemann, N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6826 · Cited by 99
Costantini, D. L., Bateman, K., McLarty, K., Vallis, K. A., & Reilly, R. M. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.051771 · Cited by 97
Geldanamycin Induces ErbB-2 Degradation by Proteolytic Fragmentation
Tikhomirov, O., & Carpenter, G. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003114200 · Cited by 75
V‐ATPase inhibition overcomes trastuzumab resistance in breast cancer
von Schwarzenberg, K., Lajtos, T., Simon, L., Müller, R., Vereb, G., & Vollmar, A. M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.011 · Cited by 67
Nahta, R., Shabaya, S., Ozbay, T., & Rowe, D. (2009) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569209790112337 · Cited by 66
Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., & Fujii, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0424 · Cited by 59
Lee, G., Kim, D., Kim, H., Lee, J.-W., Chung, C.-H., Ahn, T., Lim, J. M., Kim, I., Chae, H., & Kim, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.167734 · Cited by 41
Liddil, J. D., Dorr, R. T., & Scuderi, P. (1989) · PubMed · Cited by 37
Barbareschi, M., Cuorvo, L. V., Girlando, S., Bragantini, E., Eccher, C., Leonardi, E., Ferro, A., Caldara, A., Triolo, R., Cantaloni, C., et al. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1267-2 · Cited by 28
Tan, X., Jin, G., Myers, J. S., Diesl, V., Follettie, M. T., Lam, M., Musto, S., Khandke, K. M., Charati, M. B., Graziani, E. I., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4629 · Cited by 18
Cited by
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Metadata
- Authors
- Barok, M., Joensuu, H., & Isola, J.
- Venue
- Breast Cancer Research
- Published
- 2014-03-05
- Volume
- 16
- Issue
- 2
- Pages
- 209-209
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2162488896
- Cited by
- 595
- References
- 78
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.